Xencor (XNCR) is Initiated by Canaccord Genuity to Buy, Price Target at $20

Xencor (XNCR) is Initiated by Canaccord Genuity to Buy according to the research report released to the investors. The brokerage firm has set the Price Target of the shares at $20. The shares recommendation by the Brokerage Firm was released on Dec-22-2015.

Shares of Xencor, Inc. (NASDAQ:XNCR) ended Thursday session in red amid volatile trading. The shares closed down 0.47 points or 3.08% at $14.8 with 352,615 shares getting traded. Post opening the session at $15.29, the shares hit an intraday low of $14.63 and an intraday high of $15.58 and the price vacillated in this range throughout the day. The company has a market cap of $599 million and the number of outstanding shares has been calculated to be 40,477,003 shares. The 52-week high of Xencor, Inc. (NASDAQ:XNCR) is $24.82 and the 52-week low is $10.68.

Analysts at Zacks have given a short term rating of hold on Xencor, Inc. (NASDAQ:XNCR) with a rank of 3. The shares has received an average rating of 1 from 3 brokerage firms. 3 analysts have rated the company as a strong buy.

Xencor, Inc. (NASDAQ:XNCR) shares are expected to touch $25.67 in the short term. This short term price target has been shared by 3 analysts. However, the standard deviation of short term price estimate has been valued at 3.21. The target price could hit $28 on the higher end and $22 on the lower end.

Shares of Xencor, Inc. rose by 4.37% in the last five trading days and 14.64% for the last 4 weeks. Xencor, Inc. has dropped 20.81% during the last 3-month period . Year-to-Date the stock performance stands at -7.73%.

Xencor, Inc. (Xencor) is a clinical-stage biopharmaceutical company. The Company focused on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. The Company uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions. The Company pipeline includes XmAb5871, XmAb7195 and XmAb5574/MOR208. XmAb5871 is being developed for the treatment of autoimmune diseases, including rheumatoid arthritis and lupus. XmAb7195 is being developed for the treatment of severe asthma and allergic diseases. XmAb5574/MOR208 is being developed for the treatment of blood-based cancers and uses our Cytotoxic Fc Domain.